bluebird bio, Inc.

bluebird bio, Inc.

bluebird bio, Inc.

Overview
Date Founded

1993

Headquarters

60 BINNEY STREET, CAMBRIDGE, MA, 02142

Type of Company

Public

Employees (Worldwide)

1,213

Industries

Biotechnology
IT Consulting & Services
Medical Support Services

Company Description

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at bluebird bio, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial & Accounting Officer

Chief Operating & Legal Officer

Chief Technology & Manufacturing Officer

Chief Scientific Officer

Chief People Officer

Head of Europe

Head of Europe

President, Severe Genetic Diseases

Senior Vice President & Franchise Head for Severe Genetic Diseases

Board of Directors

Former Venture Partner at Third Rock Ventures LLC

Chief Executive Officer at bluebird bio, Inc.

Professor-Medicine at Dana-Farber Cancer Institute, Inc.

Chief Executive Officer at Herbalife Nutrition Ltd.

Senior Advisor at The Monitor Group, Inc. - Georgia

Executive Vice President & President, Sales & Operations at Change Healthcare Corp.

Founder at The Mentoring Place

Co-Founder at Forbion Capital Partners Management Holding BV

Former Senior Medical Director-Clinical Development at MedImmune LLC

Paths to bluebird bio, Inc.
Potential Connections via
Relationship Science
You
bluebird bio, Inc.
Owners & Shareholders
Details Hidden

RBC GAM-UK employs fundamental analysis and quantitative analysis. Individual portfolio managers may emphasize one method of security analysis over another in providing investment management services to discretionary clients and recommendations to nondiscretionary clients. The firm’s investment teams are responsible for researching investment opportunities, and implementing their findings and views on specific issuers in the management of clients’ portfolios. RBC GAM-UK employs various investment strategies through our investment mandates that are based on the objectives and strategies of the clients involved.

Details Hidden

Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund firm which focuses primarily on the health care and consumer sectors. They invest predominantly in equities and can be opportunistic across the capital structure. The firm seeks to maximize the opportunity set of investment candidates allowing for the selection of unique, concentrated bets to generate uncorrelated returns. They maintain significant position and portfolio level hedges in an effort to mitigate basis and market risks. Armistice Capital employs a bottom-up analysis, assessing all components of the company’s capital structure and aims to take larger positions where the greatest potential risk adjusted return exists. Armistice Capital’s Domestic Fund and the Offshore Fund, through their investments in the Master Fund, seek to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing in distressed debt, value equities and event equities. In all of its investing activities, the Funds will seek to emphasize capital preservation and will seek to mitigate risk through various hedging strategies at both the position and portfolio levels.

Details Hidden

Sessa Capital seeks to outperform the broad equity indices over each investment cycle as well as over the life of the funds. The firm utilizes a value and special situation investment approach. They invest client assets in a wide range of asset classes and geographies. On the short side, Sessa Capital expects to sell short equities, fixed income, and other financial instruments that reflect failing businesses, troubled operations, unsustainable capital structures, rich valuations, accounting irregularities, suspect promotions, and theme based shorts, among others. Additionally, shorts may be used to hedge certain exposures on the long side or to hedge the overall portfolio. On the long side, the firm expects to mostly purchase equity securities and securities that can provide equity-like returns.

Recent Transactions
Details Hidden

bluebird bio, Inc. issued USD Common Stock

Details Hidden

bluebird bio, Inc. issued USD Common Stock

Details Hidden

bluebird bio, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onbluebird bio, Inc. issued USD Common Stock

Underwriter

Advised onbluebird bio, Inc. issued USD Common Stock

Underwriter

Advised onbluebird bio, Inc. issued USD Common Stock

Legal Advisor

Advised onbluebird bio, Inc. issued USD Common Stock

Professional

Advised onbluebird bio, Inc. issued USD Common Stock

Managing Director, ECM

Advised onbluebird bio, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

National Co-Chair, Life Sciences Practice at Goodwin Procter LLP

Legal Advisor

Partner at Ropes & Gray LLP

Consultant

Former Chief Financial Officer & Treasurer at bluebird bio, Inc.

Clients

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Key Stats and Financials As of 2020
Market Capitalization
$2.22B
Total Enterprise Value
$1.73B
Earnings Per Share
$-9.95
Net Profit
$-619M
EBITDA
$-610M
EBITDAMargin
-243.35%
Total Debt
$193M
Total Equity
$1.36B
Enterprise Value / Sales
6.9x
TEVNet Income
-2.8x
Debt TEV
0.11x
Revenue
$251M
Three Year Compounded Annual Growth Rate Of Revenue
92%
Non-Profit Donations & Grants
Investments
Details Hidden

TC Biopharm Ltd. provides research services. The firm specializes in clinical grade cell therapy, cancer immonotherapy, regenerative medicine, and stratified medicine. The company was founded by Michael Leek, Angela Scott and David Galagher in 2014 and is headquartered in Edinburgh, the United Kingdom.

Investors
Details Hidden

Nazem's investment strategy is to identify and secure positions in those industries that will forge new standards and technologies that will lead the markets and economies of tomorrow while adhering to classical business theories. They seek to identify the most fertile and burgeoning sectors in healthcare services, biotechnology/life sciences, electronics, information technology, telecommunications and the Internet.The firm invests in all stages of enterprise development, from seed-stage to follow-on financings to late-stage pre-IPO financings. They also invest in stress and turnaround situations where they can lead the reorganization efforts.

Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

Third Rock Ventures invests in companies located in the US. The firm targets operating in the fields of healthcare sector. It provides financing for early-stage capital requirements. It also acts as a lead investor.

Suppliers
Massachusetts Institute of Technology Hospitals & Patient Services | Cambridge, Massachusetts

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Institut Pasteur Investment Services & Portfolio Management | Paris, France

The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris.

Stanford University Biotechnology | Stanford, CA

Stanford University, officially Leland Stanford Junior University, is a private research university in Stanford, California. Stanford was founded in 1885 by Leland and Jane Stanford in memory of their only child, Leland Stanford Jr., who had died of typhoid fever at age 15 the previous year. Stanford is generally ranked among the best universities in the world by academic publications. It is also one of the top fundraising institutions in the country, becoming the first school to raise more than a billion dollars in a year.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Agios Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Awards & Honors
2014
World Economic Forum - Technology Pioneers
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by bluebird bio, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of bluebird bio, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and bluebird bio, Inc..